Daiichi Sankyo Reports Decreases in Sales, Profits in Apr-Sept Term by Slump of Ranbaxy, Return of Marketing Rights

November 1, 2011
In its consolidated settlement of accounts for April-September 2011 announced on October 31, Daiichi Sankyo posted sales of ¥456.042 billion (-8.6% compared to the corresponding period of the previous year) as a result of the negative impacts, including a decrease...read more